Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
ENTA•Loss widens in the quarter
The company posted a wider net loss of $19.5 million for the fiscal third quarter.
Key details for the period included:
- Q3 loss per share: $0.67
- Q3 operating expenses: $31.6 million
- Q3 operating income: -$17.24 million
- Q3 pretax loss: $19.47 million
Outlook and analyst coverage
Enanta said it expects cash and marketable securities to fund operations into fiscal 2029.
The company said it remains on track to initiate the RESOLVE Phase 2b/3 RSV trial in 4Q 2026 and expects topline data from the EDP-978 Phase 1 trial in 4Q 2026.
Analyst coverage remains positive, with the current average rating on the shares at buy. Wall Street’s median 12-month price target is $20.00, about 45.2% above the August 7 closing price of $13.77.
